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Abstract 
Background: After definitive chemoradiotherapy for non-metastatic nasopharyngeal carcinoma (NPC), more than 
10% of patients will experience a local recurrence. Salvage treatments present significant challenges for locally recur-
rent NPC. Surgery, stereotactic ablative body radiotherapy, and brachytherapy have been used to treat locally recur-
rent NPC. However, only patients with small-volume tumors can benefit from these treatments. Re-irradiation with 
X-ray—based intensity-modulated radiotherapy (IMXT) has been more widely used for salvage treatment of locally 
recurrent NPC with a large tumor burden, but over-irradiation to the surrounding normal tissues has been shown to 
cause frequent and severe toxicities. Furthermore, locally recurrent NPC represents a clinical entity that is more radio-
resistant than its primary counterpart. Due to the inherent physical advantages of heavy-particle therapy, precise dose 
delivery to the target volume(s), without exposing the surrounding organs at risk to extra doses, is highly feasible 
with carbon-ion radiotherapy (CIRT). In addition, CIRT is a high linear energy transfer (LET) radiation and provides an 
increased relative biological effectiveness compared with photon and proton radiotherapy. Our prior work showed 
that CIRT alone to 57.5 GyE (gray equivalent), at 2.5 GyE per daily fraction, was well tolerated in patients who were pre-
viously treated for NPC with a definitive dose of IMXT. The short-term response rates at 3–6 months were also accept-
able. However, no patients were treated with concurrent chemotherapy. Whether the addition of concurrent chemo-
therapy to CIRT can benefit locally recurrent NPC patients over CIRT alone has never been addressed. It is possible that 
the benefits of high-LET CIRT may make radiosensitizing chemotherapy unnecessary. We therefore implemented a 
phase I/II clinical trial to address these questions and present our methodology and results.
Methods and design: The maximal tolerated dose (MTD) of re-treatment using raster-scanning CIRT plus concur-
rent cisplatin will be determined in the phase I, dose-escalating stage of this study. CIRT dose escalation from 52.5 to 
65 GyE (2.5 GyE × 21–26 fractions) will be delivered, with the primary endpoints being acute and subacute toxicities. 
Efficacy in terms of overall survival (OS) and local progression-free survival of patients after concurrent chemotherapy 
plus CIRT at the determined MTD will then be studied in the phase II stage of the trial. We hypothesize that CIRT plus 
chemotherapy can improve the 2-year OS rate from the historical 50% to at least 70%.
Conclusions: Re-treatment of locally recurrent NPC using photon radiation techniques, including IMXT, provides 
moderate efficacy but causes potentially severe toxicities. Improved outcomes in terms of efficacy and toxicity profile 
are expected with CIRT plus chemotherapy. However, the MTD of CIRT used concurrently with cisplatin-based chemo-
therapy for locally recurrent NPC remains to be determined. In addition, whether the addition of chemotherapy to 
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Background
Despite substantial improvements in treatment outcomes 
for nasopharyngeal carcinoma (NPC) owing to new 
radiation technologies, such as X-ray—based intensity-
modulated radiotherapy (IMXT), and concurrent chemo-
radiotherapy, local recurrence remains a common reason 
for treatment failure. Unfortunately, approximately 10%–
15% of patients with non-metastatic disease will expe-
rience local recurrence after high-dose IMXT, with or 
without chemotherapy [1]. Re-treatment with definitive 
intent after high-dose IMXT poses a significant challenge 
to oncologists who specialize in head and neck cancer.
Several modalities have been used with some success in 
the re-treatment of local NPC when the initial treatments 
failed. For example, nasopharyngectomy, for a selected 
group of NPC patients with limited tumor volume in the 
post-nasal space, might achieve a long-term control rate 
of over 50% [2]. Re-irradiation using stereotactic radio-
surgery or brachytherapy can also be used for recurrent 
foci with limited tumor volume [3, 4]. However, for more 
extensive local recurrences after high-dose radiation, 
IMXT is currently the treatment of choice in the endemic 
region. Several retrospective studies have addressed 
the long-term results of using IMXT for locally recur-
rent NPC; the documented 3- to 5-year overall survival 
(OS) rates for most patients who presented with locally 
advanced recurrent disease were usually less than 40% 
[5–7].
Challenges in the re‑treatment of locally recurrent NPC
Re-irradiation of locally recurrent NPC after a prior 
course of definitive radiation is challenging for many rea-
sons. The high-dose volumes encompassed in the initial 
course of definitive radiotherapy for the primary dis-
ease consist of not only the gross tumor volume (GTV) 
but also the organs at risk (OARs), such as the pharyn-
geal mucosa, optic nerve/chiasm, temporal lobes of the 
brain, and brain stem, as necessitated for the coverage 
of subclinical disease. A substantial portion of the tem-
poral lobes and most parts of the nasopharynx are often 
irradiated with a dose of 66–70 Gy, especially in patients 
with locally advanced recurrences. When the combined 
radiation dose of both initial radiotherapy and re-irradi-
ation exceeds 100 Gy, the likelihood of radiation-induced 
adverse effects increases substantially (from 4% to 39%) 
[8]. Therefore, re-irradiation to a dose that exceeds 60 Gy 
may cause severe long-term adverse effects, including 
temporal lobe necrosis and soft-tissue ulceration and 
necrosis. Nasopharyngeal mucosal ulceration and necro-
sis is a potentially life-threatening condition. In addi-
tion to causing a significant reduction in quality of life, 
high-dose re-irradiation can cause death from necrosis, 
infection, or massive hemorrhage of the internal carotid 
artery, despite optimum clinical management.
Local recurrence of NPC after definitive radiotherapy 
with photons is most likely caused by radio-resistant 
NPC cells that survived the first course of radiation. 
Treatments might also fail locally due to the techni-
cal limitations of two-dimensional conventional radio-
therapy or three-dimensional conformal radiotherapy, 
in which inadequate imaging, targeting, and delivery 
reproducibility may result in under-dosing of the pri-
mary disease and neck adenopathy. The prevailing use of 
IMXT, along with advanced imaging technology such as 
magnetic resonance imaging (MRI) and positron emis-
sion tomography/computed tomography (PET/CT), have 
significantly improved locoregional disease control over 
the years. Despite these advances, 10%–15% of patients 
who complete IMXT at 70 Gy still experience local treat-
ment failure [1]. Therefore, having largely eliminated the 
technological limitations of treatment, it is reasonable 
to speculate that there are subgroups of cells within the 
gross disease that are more resistant to X-ray—based 
radiation and are enriched within recurrent tumors. 
Whether such features of radio-resistance are secondary 
to inherently radio-resistant clones, the presence of can-
cer stem cells, or hypo-oxygenation remains unknown. 
Regardless of the mechanisms, radio-resistance of the 
recurrent tumor confers a worse outcome after re-
treatment using IMXT with doses similar to the initial 
radiotherapy (i.e., 60–70  Gy at standard fractionation). 
Thus, previous IMXT for primary NPC poses additional 
biologic challenges to re-treatment of local recurrence. 
This clinical scenario requires the targeting of a more 
radio-resistant disease while several critical OARs may 
have already been encompassed in the high-dose region. 
Nearly all patients reported in the literature so far were 
treated with two-dimensional conventional radiotherapy. 
As such, previous data may not be comparable to studies 
conducted in the IMXT era.
CIRT is needed remains unknown. These questions will be evaluated in the dose-escalating phase I and randomized 
phase II trials.
Keywords: Recurrent nasopharyngeal cancer, Carbon ion radiotherapy, Re-irradiation, Salvage therapy, 
Chemotherapy
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Characteristics of particle radiotherapy in cancer treatment
Charged-particle therapy, such as proton therapy, helium 
therapy, and carbon-ion radiotherapy (CIRT), possess 
distinct physical characteristics that make it superior to 
photon therapy. These include a sharp lateral penum-
bra; minimal energy deposition within the beam’s entry 
path prior to the Bragg peak, which is defined by its steep 
dose deposition; and a sharp dose-deposition fall-off after 
the Bragg peak. Thus, beams exhibit both a precise and 
a finite range with respect to their dose delivery capabil-
ity. The depth of the Bragg peak can be altered by altering 
the beam’s energy. These properties enable the sparing of 
surrounding normal tissues, which is crucial when irradi-
ating the head and neck area, especially for patients who 
have received prior radiotherapy to this region. Several 
reports have shown improved dose distributions using 
particle therapy for primary or recurrent NPC, with 
acceptable efficacy and toxicity profiles [9–11].
In addition to its superior dosimetric properties, the 
heavy carbon ion is a high linear energy transfer (LET) 
modality. Furthermore, the relative biological effectiveness 
(RBE) of CIRT is substantially higher than that of photon- 
and even proton-based radiation. The value of RBE is 3–5 
for carbon ion. The actual calculated value is dependent 
on both the tissue type and the biologic endpoint of RBE 
assessment. High-LET radiation inflicts more damage via 
direct DNA double-strand breaks, which are more dif-
ficult to repair [12]. Improved efficacy could be expected 
after the delivery of high-LET radiation, such as CIRT, 
especially in the treatment of photon-resistant cancer cells 
that have been selected for their ability to more efficiently 
repair DNA single-strand breaks. Per convention with 
CIRT (and other particle-based modalities), the differ-
ences in RBE and LET between CIRT and photon radio-
therapy will be taken into account, and the CIRT doses will 
be reported in terms of gray equivalents (GyE), which refer 
to the biologic effective doses (BEDs) of photons.
Results from retrospective and prospective studies 
have shown improved outcomes after CIRT for several 
malignancies, including chordoma/chondrosarcoma of 
the skull base [13, 14], melanoma [15], and adenoid cystic 
carcinoma of the head and neck region [16]. These results 
also demonstrated the safety of CIRT to critical OARs 
such as the optical nerve/chiasm, brain, brainstem, and 
spinal cord. At the Heidelberg Ion-Beam Therapy Center 
in Germany and the National Institute of Radiological 
Sciences in Japan, CIRT is currently the routine treat-
ment for patients with these conditions.
Particle therapy for local recurrence in head and neck 
cancers
Particle therapy has also been used successfully in the re-
treatment of local recurrences of the above-mentioned 
conditions of the head and neck, including locally recur-
rent NPC. In one study, 16 NPC patients who devel-
oped a local recurrence after conventional photon-based 
radiotherapy and were re-irradiated by proton radiation 
achieved an OS rate of 50% [11]. Those who were re-irra-
diated with 61 Gy or more achieved a local control rate 
of 60%; however, the local control rate was only 38% for 
those irradiated with a lower total dose (P = 0.17) [11]. 
The median cumulative dose of both the initial radiother-
apy and re-irradiation was 133.5 Gy (range, 110–148 Gy). 
The 2 of 9 (22.2%) surviving patients who developed 
osteonecrosis and mucosal necrosis were successfully 
treated with surgical debridement and hyperbaric oxy-
gen. With radiation doses of 60.0, 60.0, and 57.0 Gy to the 
optic chiasm, surface of the brainstem, and center of the 
brainstem, respectively, no patient experienced clinically 
detectable neurological dysfunction [11].
A series from the Heidelberg Ion-Beam Therapy Center 
included 18 patients with base-of-skull tumors who 
developed local recurrences after an initial course of radi-
otherapy and were re-irradiated with CIRT to a median 
dose of 51 GyE (range, 42–60 GyE) over 17 consecutive 
days (3 GyE per daily fraction) [17]. In this study, 3 of 18 
patients received two courses of radiotherapy prior to the 
re-irradiation and received CIRT for their third course. 
Based on this calculation, the cumulative biological effec-
tive dose with an α/β ratio of 2 (BED2; usually for late-
responding tissue) and cumulative biological effective 
dose with an α/β ratio of 9 (BED9; usually for tumor and 
early-responding tissue) were 127.5 and 68 GyE, respec-
tively, using an α/β value of 2 for late toxicity of normal 
tissue. No patient developed grade 3 or 4 early or late 
toxicities.
Concurrent chemotherapy with CIRT for locally recurrent 
NPC
Concurrent chemotherapy with IMXT is the current 
standard treatment for locally advanced NPC and has 
been studied against other chemotherapy scheduling [18, 
19]. However, the addition of chemotherapy during IMXT 
for re-irradiation of locally recurrent NPC has never been 
studied in any prospective clinical trial. In the above-men-
tioned retrospective studies, some patients with recurrent 
NPC were treated with IMXT plus chemotherapy (either 
concurrent or adjuvant). However, multivariate analyses 
did not confirm that the addition of chemotherapy was a 
significant prognostic factor. The underlying mechanism 
of chemotherapy used with radiotherapy for recurrent 
NPC is not clear. However, in vitro studies have indicated 
the chemo-resistant characteristics of NPC stem cells 
[20]. It is reasonable to presume that locally recurrent 
NPC foci harbor chemo-resistant (and radio-resistant) 
cells that may reduce the efficacy of chemotherapy. In 
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addition, the early onset of life-threatening adverse effects 
may mask the synergistic effects of combined chemora-
diotherapy on disease control and survival.
The combination of CIRT with concurrent chemo-
therapy has never been studied prospectively for any 
malignancy. Given the superior physical and biological 
properties of CIRT and the potential benefits of concur-
rent chemotherapy, it is also reasonable to postulate that 
CIRT plus concurrent cisplatin-based chemotherapy may 
produce an optimal outcome in the treatment of locally 
recurrent NPC after high-dose IMXT. In this trial, we 
will first determine the maximal tolerated dose (MTD) of 
CIRT when used with concurrent cisplatin (weekly dose, 
40 mg/m2) for the re-irradiation of locally recurrent NPC 
after IMXT. We will then evaluate the effectiveness of 
this strategy at the MTD.
Selection of CIRT dose for re‑irradiation in the phase I 
study
In the phase I part, we will use a Time-to-Event Con-
tinual Reassessment Method (TITE-CRM) design to 
determine, via a dose-escalation scheme, the MTD for re-
irradiation using CIRT plus concurrent chemotherapy for 
the treatment of locally recurrent NPC [21, 22]. Patients 
will be monitored and evaluated for acute and subacute 
treatment-induced adverse effects, local control, local 
and distant progression-free survival, and OS.
Doses between 60 and 70 Gy (1.8/2.0 Gy per daily frac-
tion) were commonly used for re-irradiation with IMXT 
for the treatment of locally recurrent NPC. Unfortu-
nately, this dose range is associated with at least 35% of 
severe adverse effects (defined as grades 3–5 toxicities), 
including soft-tissue ulceration and hemorrhage, espe-
cially at higher doses [5, 7]. In a series of 239 patients 
treated with a mean dose of 70.04  Gy (range, 61.73–
77.54 Gy) to the GTV, grades 3–5 re-irradiation-induced 
severe late toxicities occurred in approximately 52% of 
the patients and were the cause of death of almost 70% of 
the 120 patients who died [7]. More recently, in a study of 
salvage IMXT for the treatment of locally recurrent NPC 
after previous definitive IMXT, Kong et al. [23] reported 
a similar rate of severe toxicity (approximately 40%) after 
re-irradiation using IMXT. In addition, many patients 
developed two or more late toxicities after retreatment, 
and almost 70% of mucosal necrosis occurred within 
6  months after re-treatment. Currently, a reduced dose 
range from 60 to 66 Gy at conventional fractionation (i.e., 
BED9 73–81  GyE) is commonly used for re-irradiation 
with IMXT for the treatment of locally recurrent NPC. 
However, long-term results after treatment at this dose 
level, especially for patients who recurred after receiv-
ing definitive IMXT for their primary treatment, have not 
been reported.
Two articles on re-irradiation using proton or heavy-
particle therapy have reported clinically acceptable 
long-term toxicity outcomes. In these studies, a BED2 
of approximately 120 GyE was delivered to the recurrent 
tumor. Doses of re-irradiation using proton and carbon 
ion exceeding or below 120 GyE conferred grade 3/4 late 
toxicity rates of approximately 22% and 0%, respectively 
[11, 17]. A total dose of 55  GyE (at 2.5  GyE per daily 
fraction) resulted in a BED2 of 124 GyE and a BED9 of 
70 GyE. Since concurrent chemotherapy with CIRT may 
provide additive, if not synergistic, effects on efficacy as 
well as toxicity, 55 GyE at 2.5 GyE/day should serve as an 
acceptable starting dose/fraction schedule. In our previ-
ous phase I/II trial on CIRT alone for the treatment of 
locally recurrent NPC, we chose 57.5  GyE as the start-
ing dose [24]. Owing to the potential additive toxicity of 
concurrent chemotherapy combined with CIRT, it will be 
prudent to set the starting dose of the phase I trial some-
what lower, at 55 GyE delivered at 2.5 GyE/day.
Because of the sharper penumbra offered by CIRT, we 
anticipate that the delivery of higher doses to the clini-
cal targets—while potentially lowering the integral dose 
to, and high-dose volumes within, the non-targeted 
structures—will be more feasible compared with tra-
ditional photon-based radiotherapy. Because of these 
unique properties of CIRT, in addition to determin-
ing the straightforward MTD, toxicity will be associ-
ated with other unique dosimetric characteristics, such 
as dose-volume histogram parameters and gradient and 
conformality indices of the various BEDs within normal 
structures and tissues. This will provide supplemental 
three-dimensional and dynamic information to deter-
mine the tolerance of previously treated tissues to CIRT. 
Lastly, we will be able to determine the additive or syner-
gistic effects of adding platinum-based chemotherapy to 
CIRT, as previous studies, with toxicity data, have con-
sisted primarily of CIRT-alone regimens.
Methods and design
As a single-center, single-arm phase I/II clinical trial, its 
purposes are to determine the MTD of re-irradiation 
using CIRT combined with concurrent cisplatin-based 
chemotherapy in the treatment of locally recurrent NPC 




The primary objective is to determine the MTD of CIRT 
combined with concurrent chemotherapy in the treat-
ment of locally recurrent NPC, by observing the acute 
or subacute grade 4 or 5 toxicities [Common Terminol-
ogy Criteria for Adverse Events (CTCAE) v. 4.03] that 
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are possibly, probably, or definitively caused by the treat-
ments [25]. The secondary objective is to evaluate the 
local progression-free survival and OS after re-irradia-
tion using the combined treatment.
Phase II trial
The primary endpoint is 2-year OS after salvage CIRT 
with concurrent chemotherapy. The secondary endpoints 
are local control, disease-free survival, and long-term 
toxicity and safety.
Trial design and schedule
Phase I trial: dose escalation to determine MTD
The purpose of the phase I trial is to determine the 
MTD of salvage raster-scanning CIRT with concur-
rent cisplatin-based chemotherapy for locally recur-
rent NPC. Patients who meet the inclusion criteria will 
be treated with chemotherapy and this dose-escalating 
CIRT scheme, and acute and subacute toxicity during 
the treatments and within 4 months after CIRT will be 
observed.
The study includes 6 increasing dose regimens start-
ing at 52.5  GyE (2.5  GyE ×  19 fractions) up to 65  GyE 
(2.5 GyE × 26 fractions) using the TITE-CRM design of 
phase I trials, with the starting dose/fraction at 55  GyE 
delivered daily in 22 fractions. The trial will be concluded 
at 65 GyE if the MTD is not reached, and 65 GyE/26 frac-
tions will be the recommended dose/fractions for the 
phase II trial. The probability of dose limiting toxicity 
(pDLT) for each dose level is estimated based on pub-
lished data for re-irradiation with CIRT to the head and 
neck area (Table 1).
A maximum of 25 patients for the 6 dose levels (start-
ing at 55 GyE) is projected for phase I trial (i.e., the dose-
escalating stage of the trial). Based on our clinical load, 
we expect to recruit an average of 1 patient per week. 
We expect that the phase I trial will be completed in 
24 months, since the first patient at each dose level will 
be followed up for 4 months before dose escalation.
Phase II trial: treatment at recommended dose to study 
efficacy
Once the MTD is determined in the phase I trial, this 
dose will be used as the recommended dose for the phase 
II trial. If MTD is not reached at 65  GyE, we will use 
65 GyE as the recommended dose.
The primary endpoint of the phase II trial is OS after 
re-irradiation, at a median follow-up of 24  months. To 
evaluate the OS rate, all patients will be followed up for 
at least 12  months or until death. We estimate that 1 
patient per week will be recruited to the trial, and a total 
of 40 patients (minus the number of patients treated 
at the recommended dose in the phase I trial) will be 
recruited over approximately 9 months. The phase II trial 
is expected to be completed in 24 months.
Inclusion and exclusion criteria
For this trial, all patients with a confirmed diagnosis of 
locally recurrent NPC will be evaluated and screened. 
Inclusion and exclusion criteria are listed in Table 2.
Induction, concurrent, and adjuvant treatments
Induction and adjuvant chemotherapy
Induction chemotherapy (with or without targeted ther-
apy) will be administered to patients with rT3, rT4, or 
rN+ disease (excluding those with retroperitoneal lymph 
node recurrence only) unless clinically contraindicated. 
Induction chemotherapy is not mandatory for patients 
with rT1, rT2, or recurrent retropharyngeal node dis-
ease only. Routine adjuvant chemotherapy is not allowed. 
Patients with local recurrence/progression or distant 
metastasis after re-irradiation with CIRT can be consid-
ered for salvage chemotherapy.
Concurrent chemotherapy
The administration of concurrent cisplatin-based chemo-
therapy will start on the first day of CIRT and will consist 
of weekly cisplatin (40 mg/m2) during CIRT for a maxi-
mum of 5 cycles. Chemotherapy at the full dose will be 
Table 1 Treatment schedule (CIRT plus concurrent chemotherapy) for dose escalation in patients with  locally recurrent 
nasopharyngeal carcinoma (NPC)
The starting dose of the trial is at 2.5 GyE × 22 (in italics)
CIRT carbon-ion radiotherapy, GyE gray equivalent, pDLT probability of dose-limiting toxicities, BED biological effective dose, BED2 cumulative BED with an α/β ratio of 
2, BED9 cumulative BED with an α/β ratio of 9
 Dose level Dose and fractionation Total dose (GyE) pDLT (%) BED2 (GyE) BED9 (GyE)
1 2.5 GyE × 21 fractions 52.5 <5 118.1 67.1
2 2.5 GyE × 22 fractions (starting dose) 55 10 123.8 70.3
3 2.5 GyE × 23 fractions 57.5 20 129.4 73.5
4 2.5 GyE × 24 fractions 60 30 135.0 76.7
5 2.5 GyE × 25 fractions 62.5 40 140.6 79.9
6 2.5 GyE × 26 fractions 65 50 146.3 83.1
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delivered, and no adjustment will be allowed unless grade 
4 chemotherapy-induced toxicities occur. The start of 
chemotherapy can be postponed if a patient’s neutrophil 
count drops below 2000/µL or the platelet count drops 
below 100,000/µL. Chemotherapy can be suspended if a 
patient’s creatinine clearance rate is less than 50 mL/min.
Other medications
Prescription medication required for the treatment of 
medical conditions other than NPC is allowed during the 
phase II trial. However, any treatments not related to the 
trial must be discussed with and thoroughly reviewed by 
the principal investigator prior to a patient’s inclusion.
Radiation therapy1
Treatment planning
Patients will be immobilized using an individual immo-
bilization system for planning and treatment. Planning 
CT without contrast will be performed; MRI scans in the 
treatment position will be obtained, registered, and fused 
with a planning CT.
  • GTV is defined as the gross disease seen on the 
planning CT, area of contrast enhancement on 
T1-weighted MRI, and/or lesion(s) with high stand-
ardized uptake value observed on fluoro-d-glucose-
PET/CT (optional).
  • Clinical target volume (CTV) is defined as the GTV 
plus a 3 to 5-mm margin. The CTV for subclinical 
disease will be delineated based on the treating physi-
1 The radiotherapeutic techniques, doses used and treatment goals, assess-
ment of efficacy parameters, and statistical calculation of this clinical trial 
are similar/identical to those of our previous clinical trial of CIRT alone 
[24]. However, for clarity, practicality, and ease of reading, our methods 
within the context of this proposal are still described in their respective sec-
tions.
cian’s clinical judgment for potential subclinical dis-
ease.
  • Planning target volume (PTV) will be added depend-
ing on individual factors such as patient positioning 
reproducibility and/or beam angles chosen and will 
range from 3 to 6 mm.
Critical OARs, including the brain stem, optic nerve, 
optic chiasm, temporal lobes of the brain, and eyes, will 
be contoured. A dose discount to OARs from the initial 
radiation course will be uniformly set at 70%; thus, 30% 
residual doses will be used to calculate the limiting dose 
to the OARs. Dose limitations of OARs will be controlled 
according to those reported by Emami et al. [26].
CIRT planning will be performed using the Syngo 
treatment planning system (Siemens; Erlangen, Ger-
many), including biologic plan optimization. BED distri-
butions will be calculated using the generally accepted 
an α/β ratio of 9 for NPC and an α/β ratio of 2 for late-
responding tissues (generally presented as late toxicity).
Dose prescription for CIRT
Re-irradiation using intensity-modulated CIRT will be 
delivered using the IONTRIS raster scan system (Siemens 
Aktiengesellschaft, Munich, Germany). Six dose levels 
and the estimation of pDLT of each level are detailed 
in Table 1. A daily dose of 2.5 GyE will be delivered up 
to the total dose for all levels and be given concurrently 
with chemotherapy (see “Chemotherapy” above). After 
the MTD is determined or if the treatments to 65  GyE 
are safely delivered, the delivered dose (or 65 GyE) will be 
defined as recommended dose and used as the prescribed 
dose in the phase II stage of the study.
Ninety-five percent of the isodose line should cover the 
CTV for gross tumor (i.e., GTV plus 3–5 mm), and 90% 
of the dose line should cover the PTV for gross disease. 
Table 2 Inclusion and exclusion criteria for the phase I/II CIRT plus chemotherapy dose escalation trial for NPC
CIRT carbon-ion radiotherapy, IMXT X-ray–based intensity-modulated radiotherapy, KPS Karnofsky performance status, SRS stereotactic radiosurgery, CIS carcinoma 
in situ
Inclusion criteria Exclusion criteria
Pathologically and/or clinically confirmed locally recurrent NPC diagnosed 
more than 12 months after completion of initial IMXT
Completed a definitive course of IMXT to a total dose of ≥66 Gy
Age ≥18 and <70 years
KPS score ≥70
Ability to understand the trial protocol, including the aims, methods, and 
consequences
Willingness to provide written informed consent before enrollment in the 
trial
Willingness to receive the study treatment, including CIRT and cisplatin-
based concurrent chemotherapy
For women with childbearing potential, willingness to use adequate 
contraception
Presence of distant metastasis
Recurrence diagnosed within 12 months after the completion of the 
previous IMXT course
Technology used other than IMXT (or IMXT used with other techniques, 
such as brachytherapy or SRS) for the initial treatment
Pregnant or lactating women
Patients who have not recovered from severe toxicities of prior radio-
therapy or chemotherapy
Diagnosis of any type of cancer other than CIS of the cervix and basal cell 
or squamous cell carcinoma of the skin within the past 5 years
Participation in other clinical trial(s) whose treatments may interfere with 
the conduct or outcome of this trial
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The CTV for other subclinical disease, if applicable, will 
be irradiated to 90% of the assigned dose level.
Dose specification is based on BED, because the RBE 
of CIRT differs significantly from photon therapy. There-
fore, the unit used for dose prescription is the iso-effec-
tive dose GyE daily for 5 fractions per week at 2 Gy per 
fraction.
Treatment planning and delivery
 The techniques of planning and delivery of intensity-
modulated CIRT using raster-scanning technology were 
previously described [24]. Briefly, patients are irradiated 
once a day, 5  days a week. Treatment interruptions of 
more than 3 days are not allowed, unless severe adverse 
effects require such interruption. Weekend treatment 
will be provided if a break of 2 or more days occurred 
during the previous week. Treatment positioning prior 
to intensity-modulated CIRT will be verified by compar-
ing orthogonal X-rays with the digitally reconstructed 
radiographs, and set-up deviations of more than 2  mm 
will be corrected. A typical treatment plan of a patient 
with locally recurrent NPC (rT3N0M0) is shown in 
Fig. 1.
Assessment of efficacy parameters (see footnote 1)
Baseline documentation of “target” lesion
The target lesion is defined as the gross tumor that locally 
recurred in the nasopharynx or base of skull and that is 
scheduled for re-irradiation using CIRT. The sum of the 
longest diameter (LD) for the gross tumor will be meas-
ured and reported as the baseline sum LD. The baseline 
sum LD will be used as a reference to characterize the 
objective tumor.
Response to treatment
Response to CIRT will be recorded according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) [26].
Evaluation of the target lesion by RECIST is summa-
rized below.
  • Complete response (CR): complete disappearance of 
the target lesions.
  • Partial response (PR): at least a 30% decrease in the 
LD of the target lesion, taking the baseline sum LD 
as reference.
  • Stable disease (SD): neither sufficient shrinkage to 
qualify for PR nor sufficient increase to qualify for 
PD, taking the smallest sum LD since the treatment 
started as reference.
  • Progressive disease (PD): at least a 20% increase 
in the sum of the LD of the target lesion, taking 
the smallest sum LD recorded since the treatment 
(including neoadjuvant chemotherapy) started as ref-
erence.
Evaluation of non-target lesion(s)
  • CR: disappearance of all non-target lesions and nor-
malization of tumor marker level (not applicable for 
the current study).
  • Incomplete response/SD: persistence of one or more 
non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits (not applicable 
for the current study).
  • PD: appearance of one or more new lesions and/
or unequivocal progression of existing non-target 
lesions.
Fig. 1 Typical treatment plan and dose distribution for intensity-modulated carbon-ion radiotherapy delivered using the raster-scanning technique 
in a patient with stage rT3N0M0 nasopharyngeal carcinoma with recurrence at the base of the skull. Transverse, sagittal, and coronal views are pro-
vided. The red, orange, yellow, and blue shaded areas represent 95%, 85%, 70%, and 30% isodose lines; the red, green, and yellow lines represent gross 
tumor volume (GTV), GTV + 3 mm, and clinical target volume (CTV), respectively
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Evaluation of best overall response
The best overall response will be considered the best 
extent of response recorded from the initiation of the 
study treatment until progression/recurrence of disease 
(taking as reference for PD with the smallest measure-
ment of LD recorded since the treatment started). In gen-
eral, the patient’s best response assignment will depend 
on the achievement of both measurement and confirma-
tion criteria as follows.
  • Patients will be classified as having “symptomatic 
deterioration” if, without disease progression, they 
experience an overall deterioration of general health 
status that necessitates discontinuation of chemora-
diotherapy. Documentation of objective progression 
of the disease during and after the study treatment 
will be required.
  • In some circumstances, it may be difficult to distin-
guish residual disease from normal tissue. When the 
evaluation of CR depends on this determination, it is 
recommended that the residual lesion be histologi-
cally investigated (by fine or core needle biopsy, for 
example) to confirm the CR status.
OS
The duration of OS will be calculated as the time between 
pathologic confirmation of local recurrence of NPC and 
the date of death from any cause. Patients who do not die 
or who are not lost to follow-up will be censored at the 
date of the last follow-up.
Progression‑free survival
Progression-free survival will be defined as the time 
between the initiation of neoadjuvant chemotherapy or 
the start of CIRT and the date of disease recurrence or 
progression at any body part. Patients who do not die or 
who are not lost to follow-up and present no evidence 
of disease progression will be censored at the date of the 
last follow-up.
Assessment of toxicity, safety, and other parameters
Toxicity and safety parameters
CTCAE v. 4.03 will be used for the monitoring and 
reporting of all toxicity and adverse events observed 
during and after the completion of study treatments 
[25]. Patients will be evaluated weekly by complete his-
tory, physical examination, and lab tests to determine the 
safety and toxicity of induction chemotherapy (if appli-
cable) and CIRT plus concurrent chemotherapy. These 
evaluations will be conducted at each on-treatment 
appointment and at each follow-up clinical visit.
Other parameters
Peripheral blood will be collected to measure circulat-
ing Epstein-Barr virus (EBV) DNA and/or other tumor 
markers. These parameters may be used to predict the 
extent of disease or treatment outcome, or for future 
research purposes that may or may not be directly related 
to the current trial. A separate informed consent for this 
specimen collection will be required from the patients.
Follow‑up after trial completion
Follow‑up
After completion of the study treatment, all patients 
will be required to be followed up regularly, indefinitely 
or until death, according to our institutional follow-up 
protocol for head and neck cancers. The first and second 
follow-up will be scheduled at 1 and 3 months after the 
completion of radiotherapy, respectively. Unless other-
wise clinically necessary, follow-up sessions will then 
be scheduled every 3  months in the first 3  years, every 
6 months in the following 2 years, and annually thereaf-
ter. Each follow-up examination will include a complete 
history and physical examination, MRI or CT scans with 
contrast of those for the head and neck area, and blood 
tests (including complete blood counts, serum electrolyte 
levels, pituitary function, and liver/renal function), and 
EBV DNA copies. Whole-body PET/CT scans is optional 
but preferable over thoracic and/or abdominal CT scans, 
and bone scans if clinically indicated.
Treatment at tumor progression
After completion of CIRT plus concurrent chemother-
apy, further treatment, including salvage chemotherapy, 
surgical resection, a third course of radiation for locore-
gional recurrence, systemic treatment with chemother-
apy, or targeted therapy may be clinically necessary in 
case of disease recurrence or progression. These treat-
ment decisions will be made at the discretion of the treat-
ing physician and/or team.
Statistics (see footnote 1)
Phase I trial
The primary objective is to determine the CIRT dose 
when used with concurrent cisplatin-based chemo-
therapy, which is associated with a DLT in less than 25% 
of previously treated NPC patients with a local recur-
rence. DLT is defined as any grade 4 toxicity (CTCAE v. 
4.03) that is possibly, probably, or definitely associated 
with CIRT that occurred within 6 months after comple-
tion of re-irradiation [24]. Treatment-induced adverse 
effects also include deterioration in Eastern Cooperative 
Oncology Group performance status to ≥3 that develops 
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during the same follow-up period. The secondary objec-
tives are OS and local progression-free survival. The 
MTD of CIRT for re-irradiation used with concurrent 
cisplatin-based chemotherapy will be determined at the 
end of phase I trial.
Dose levels of CIRT will be assigned based on the 
TITE-CRM algorithm [21]. During the trial, pDLT will be 
continually updated, using data from all enrolled patients 
and their updated outcomes obtained through follow-up 
visits. Patients with partial follow-up at a time of new 
enrollment (i.e., <4 months) will be weighted by the pro-
portion of the follow-up time completed. Newly enrolled 
patients will be assigned to the dose that is estimated to 
have a pDLT closest to but not higher than 0.25.
Four patients will be entered to the starting dose level. 
Dose escalation is restricted to one level between any 2 
patients. Prior to escalation, at least 1 patient must have 
completed the full course of treatment and the full obser-
vation period (6 months) at the previous dose level with-
out a DLT. Six dose levels and their initial estimation of 
the pDLT are planned within the phase I trial (Table 1). 
The dose will be increased until DLT is observed or when 
65 GyE is reached.
As described above, the phase I trial was designed to 
accrue up to 25 patients. We estimate that 4 patients will 
be accrued each month. Patients who complete 90% or 
more of the planned CIRT dose will be considered evalu-
able. Patients who complete 90% or more of the planned 
CIRT dose but become un-evaluable for 6 months will be 
counted as evaluable in the final analysis and weighted by 
the proportion of the observation period for which they 
were evaluable. Replacement of any accrued patient can 
only be considered if the patient did not complete ther-
apy for reasons other than toxicity.
At the end of the trial, a simple two-parameter logis-
tic regression model will be used to estimate the pDLT at 
each dose level. Secondary endpoints are the response of 
tumor to CIRT, local progression-free survival, OS, and 
other toxicity and safety data on the studied dose levels. 
The Kaplan–Meier method will be used to evaluate the 
OS and local progression-free survival of all patients. 
SAS v.9.1 software (SAS Institute Inc, Cary, NC, USA) 
will be used for statistical analyses. The Cox proportional 
hazards model will be used for multivariate analysis, as 
the univariate results indicate.
Phase II trial
The primary objective of the phase II trial is to evaluate 
the actuarial 2-year OS rate (π) for patients with locally 
recurrent NPC who receive CIRT plus concurrent cispl-
atin-based chemotherapy. The 2-year OS rate for patients 
with locally recurrent rT3 or rT4 NPC range from 40% to 
50% after IMXT or proton re-irradiation [5, 7].
This is the first study to address the efficacy of re-
irradiation with CIRT plus concurrent cisplatin-based 
chemotherapy on locally recurrent NPC. We estimate 
that CIRT will improve 2-year OS rate by 20% to 70%, 
compared with IMXT or proton therapy. Thus, confirma-
tory analysis of the primary endpoint assesses the follow-
ing test problem: H0: π ≤ 0.50 = π0 versus H1: π > 0.70. 
The same single-stage design will be used for the phase 
II trial [27]. The null hypothesis is defined by the true OS 
rate being 50%, and it will be tested against a one-sided 
alternative. A sample size of 37 patients will be required, 
and the null hypothesis will be rejected if 23 or more sur-
vivors are observed among 37 patients, with a median 
follow-up of 2 years. This design yields a type I error rate 
of 0.05 and a power of 0.8 if the true OS rate is 70%.
Data collection/safety/management and ethical/
legal aspects
All clinical trials of the Shanghai Proton and Heavy Ion 
Center (SPHIC) are required to adhere to the policies set 
forth by the Institutional Academic Committee and the 
Institutional Review Board (IRB). The following sections 
were adapted and summarized from the institutional pol-
icies on human studies.
Data safety monitoring board
The IRB of the SPHIC is the independent data safety 
monitoring board to monitor the recruitment, the report 
of adverse events, and the data quality for all clinical tri-
als. Data and interim results for this trial will be reviewed 
semi-annually based on the review of the trial proto-
col. The IRB will provide the principal investigator with 
requirements and recommendations on the modification 
of the trial, which may or may not include termination of 
the trial.
Data collection and management
The Chinese Good Clinical Practice regulation requires 
that all clinical trial documents be kept for at least 5 years 
after completion of the trial. The Health and Family Plan-
ning Commission of the Shanghai Municipal Govern-
ment requires that all patient medical charts, including 
all imaging studies, be maintained for at least 7  years. 
The Research Unit and the Medical Record Unit of the 
Department of Medical Affairs in the SPHIC will be 
responsible for archiving the research documents and 
medical charts, respectively.
Ethical and legal aspects
IRB approval of the current trial was obtained on Octo-
ber 30, 2015. The accrual of patients was initiated on 
November 18, 2015. The study will be conducted accord-
ing to the Good Clinical Practice guidelines of China 
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and the principles of the Declaration of Helsinki (2008 
version, adopted at the 59th World Medical Association 
General Assembly, Seoul, Korea, October 2008).
Discussion
The management of locally recurrent NPC after defini-
tive IMXT poses a major clinical challenge, since the 
recurrent disease may be more resistant to a repeated 
course of IMXT or other photon-based modalities. Previ-
ous studies of re-irradiation with IMXT showed subopti-
mal outcomes [5–7], and it is reasonable to postulate that 
recurrent lesions after definitive IMXT, which are usually 
fully encompassed by the high-dose target volume, may 
harbor cells that are more resistant to photon-based irra-
diation. Clearly, more effective local treatment is needed.
An effective re-treatment modality should have two 
important simultaneous characteristics: being efficacious 
in disease control and being mild or moderate in caus-
ing adverse effects to the surrounding OARs. Owing to 
its physical properties, CIRT is a precision radiotherapy 
modality. Additionally, it has higher RBE compared with 
lower-LET irradiation; therefore, it can be more effective 
in the treatment of neoplasms that are more resistant to 
photon or proton therapy.
Compared with IMXT or proton-beam therapy, CIRT 
for re-irradiation has been shown to improve treatment 
outcomes for several diseases [28]. Previous studies of 
CIRT in the re-treatment of locally recurrent tumors, 
including those that recurred in the base of the skull, 
after previous courses of high-dose irradiation have 
indicated overall safety and effectiveness [17]. However, 
no patients with locally recurrent NPC were included 
in any of these studies. Although the RBE of CIRT for 
NPC cells remains to be investigated, preclinical data 
have demonstrated that the RBE ranges from 2 to 5 for 
radio-resistant cells, such as glioblastoma [29, 30] and 
melanoma [31]. In addition, early results from clinical 
studies have indicated that such advantages might trans-
late into improved clinical outcomes against these resist-
ant recurrences [32].
Our previous work at the SPHIC showed that patients 
with locally recurrent NPC who received re-irradiation 
alone using intensity-modulated CIRT up to 57.5 GyE in 
25 fractions tolerated it well [24]. Within 3 months after 
completion of CIRT, most patients achieved a PR or CR, 
without grade 2 or higher radiation-induced adverse 
effects. However, longer follow-up is needed to deter-
mine the likelihood of developing late CIRT-induced 
toxicities. A phase I/II clinical trial with the aims of deter-
mining the MTD of re-irradiation with CIRT and the 
efficacy of CIRT at the MTD is ongoing [24]. Induction 
chemotherapy may be used for the treatment of locally 
advanced NPC at recurrence to reduce the tumor burden 
and to control subclinical distant metastases. However, 
chemotherapy is not being used concurrently with CIRT.
Concurrent chemotherapy with definitive radiotherapy 
has been proven effective in the treatment of NPC [18]; 
however, its effectiveness in the management of locally 
recurrent NPC has not been confirmed. In addition, the 
use of concurrent chemotherapy plus high-LET irradia-
tion, such as CIRT, for the purpose of radiosensitization 
has never been addressed. Therefore, after the initiation 
of the previous phase I/II trial that focused on CIRT 
alone and after completing the accrual of patients for 
the first dose level (57.5 GyE with a daily fraction dose of 
2.5 GyE), we initiated this trial to address the safety and 
effectiveness of CIRT plus concurrent cisplatin-based 
chemotherapy. Although all patients completed 57.5 GyE 
without experiencing any moderate or severe adverse 
effects (unpublished data), the starting dose used in the 
current study was 55  GyE, which is one echelon lower 
than the starting dose used in our CIRT-alone trial. This 
was done to avoid possible severe adverse effects from 
the potential synergistic effects of concurrent chemo-
therapy plus CIRT.
In summary, this trial will evaluate the safety and effec-
tiveness of intensity-modulated CIRT (using the pencil-
beam scanning technique) delivered concurrently with 
cisplatin-based chemotherapy to patients with locally 
recurrent NPC. In the phase I trial, dose escalation will 
be performed to determine the MTD (i.e., the recom-
mended dose) of intensity-modulated CIRT that can be 
prescribed with concurrent chemotherapy for locally 
recurrent NPC lesions. Thereafter, the phase II trial will 
address the effectiveness of intensity-modulated CIRT 
plus concurrent cisplatin at this recommended dose as 
definitive treatment for locally recurrent NPC.
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